1. Optimizing Management of Advanced Bladder Cancer

2. This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the US, and data that were presented in abstract form. These data should be considered preliminary until published in a peer-reviewed journal.

3. Systemic Therapy for Bladder Cancer Pre-2016

4. Rationale for Immunotherapy in UC

5. Immunotherapies Approved in Locally Advanced or Metastatic UC Since 2016

6. Case 1: Introduction

7. Case 1: Treatment Considerations

8. EORTC 30986: Gem/Carbo vs M-CAVI in Cisplatin-Unfit Patients With Advanced UC

9. Summary of Immunotherapies for First-Line Treatment of Metastatic UC

10. PD-L1 Expression and Responses to Immunotherapy in First-Line Metastatic UC

11. Case 1: First-Line Immunotherapy

12. Managing Immune-Related AEs: Colitis

13. Importance of Multidisciplinary Approach

14. Case 1: Follow-Up

15. Case 2: Diagnostic Workup

16. Case 2: Initial Treatment

17. Summary of Immunotherapies for Second-Line Metastatic UC

18. PD-L1 Expression and Responses to Immunotherapy in Second-Line Metastatic UC

19. Case 2: Second-Line Immunotherapy

20. Managing Immune-Related AEs: Pneumonitis

21. Planning Surgery After Systemic Therapy for Metastatic UC

22. Phase 3 Data for Checkpoint Inhibitors in Patients With Previously Treated Metastatic UC

23. Future Directions in Bladder Cancer Management

24. Concluding Remarks

25. Abbreviations

26. Abbreviations (cont)